Mersana faces the inevitable
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
Enliven seeks its reverse merger payday
Early data with ELVN-001 hold up well against olverembatinib and TERN-701.
AbbVie gets a cMet niche
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
Innovent takes the dual payload glory
IBI3020 beats Chengdu Kanghong's KH815 into clinical trials.
Erasca enters its pan-RAS era
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
Another TIGIT bites the dust
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
Qilu nabs a new B7-H3 contender
Minghui’s MHB088C will soon start phase 3 in China.
CytomX's EpCAM pivot does the job
After earlier masked probody setbacks, CytomX surprises with CX-2051.
More ROR1s enter the clinic
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
